Ehrlichiosis-Associated Hemophagocytic Lymphohistiocytosis: A Case Series and Review of the Literature

Background. Human monocytic ehrlichiosis (HME) is a potentially life-threatening tick-borne illness. HME-associated hemophagocytic lymphohistiocytosis (HLH) is a rare entity with a paucity of published literature regarding treatment and outcome. We present the clinical features, treatment, and outco...

Full description

Saved in:
Bibliographic Details
Main Authors: Kassem Hammoud, Robert Fulmer, Megan Hamner, Wissam El Atrouni
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Case Reports in Hematology
Online Access:http://dx.doi.org/10.1155/2023/5521274
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849472866626568192
author Kassem Hammoud
Robert Fulmer
Megan Hamner
Wissam El Atrouni
author_facet Kassem Hammoud
Robert Fulmer
Megan Hamner
Wissam El Atrouni
author_sort Kassem Hammoud
collection DOAJ
description Background. Human monocytic ehrlichiosis (HME) is a potentially life-threatening tick-borne illness. HME-associated hemophagocytic lymphohistiocytosis (HLH) is a rare entity with a paucity of published literature regarding treatment and outcome. We present the clinical features, treatment, and outcomes of 4 patients at our institutions with HME-associated HLH. This review also summarizes the current literature regarding the presentation, treatment, and outcome of this infection-related HLH. Methods. We searched the PubMed database for case reports and case series. All cases were diagnosed according to the HLH-04 criteria. Results. Four cases of HME-associated HLH were included from our institutions. The literature review yielded 30 additional cases. About 41% of the cases were in the pediatric population; 59% were female; and all patients had fever, cytopenia, and elevated ferritin. Most patients were immunocompetent; all but one patient with available data were treated with doxycycline, and eight of the patients with available data received the HLH-94 treatment protocol. The mortality rate was 17.6%. Conclusions. HME-associated HLH is a rare but serious syndrome with significant mortality. Early treatment with doxycycline is critical, but the role of immunosuppressive therapy is individualized.
format Article
id doaj-art-d9aba4257f7e46faaca5a929b3901a3d
institution Kabale University
issn 2090-6579
language English
publishDate 2023-01-01
publisher Wiley
record_format Article
series Case Reports in Hematology
spelling doaj-art-d9aba4257f7e46faaca5a929b3901a3d2025-08-20T03:24:22ZengWileyCase Reports in Hematology2090-65792023-01-01202310.1155/2023/5521274Ehrlichiosis-Associated Hemophagocytic Lymphohistiocytosis: A Case Series and Review of the LiteratureKassem Hammoud0Robert Fulmer1Megan Hamner2Wissam El Atrouni3Department of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Pediatric Infectious DiseasesDepartment of Infectious DiseasesBackground. Human monocytic ehrlichiosis (HME) is a potentially life-threatening tick-borne illness. HME-associated hemophagocytic lymphohistiocytosis (HLH) is a rare entity with a paucity of published literature regarding treatment and outcome. We present the clinical features, treatment, and outcomes of 4 patients at our institutions with HME-associated HLH. This review also summarizes the current literature regarding the presentation, treatment, and outcome of this infection-related HLH. Methods. We searched the PubMed database for case reports and case series. All cases were diagnosed according to the HLH-04 criteria. Results. Four cases of HME-associated HLH were included from our institutions. The literature review yielded 30 additional cases. About 41% of the cases were in the pediatric population; 59% were female; and all patients had fever, cytopenia, and elevated ferritin. Most patients were immunocompetent; all but one patient with available data were treated with doxycycline, and eight of the patients with available data received the HLH-94 treatment protocol. The mortality rate was 17.6%. Conclusions. HME-associated HLH is a rare but serious syndrome with significant mortality. Early treatment with doxycycline is critical, but the role of immunosuppressive therapy is individualized.http://dx.doi.org/10.1155/2023/5521274
spellingShingle Kassem Hammoud
Robert Fulmer
Megan Hamner
Wissam El Atrouni
Ehrlichiosis-Associated Hemophagocytic Lymphohistiocytosis: A Case Series and Review of the Literature
Case Reports in Hematology
title Ehrlichiosis-Associated Hemophagocytic Lymphohistiocytosis: A Case Series and Review of the Literature
title_full Ehrlichiosis-Associated Hemophagocytic Lymphohistiocytosis: A Case Series and Review of the Literature
title_fullStr Ehrlichiosis-Associated Hemophagocytic Lymphohistiocytosis: A Case Series and Review of the Literature
title_full_unstemmed Ehrlichiosis-Associated Hemophagocytic Lymphohistiocytosis: A Case Series and Review of the Literature
title_short Ehrlichiosis-Associated Hemophagocytic Lymphohistiocytosis: A Case Series and Review of the Literature
title_sort ehrlichiosis associated hemophagocytic lymphohistiocytosis a case series and review of the literature
url http://dx.doi.org/10.1155/2023/5521274
work_keys_str_mv AT kassemhammoud ehrlichiosisassociatedhemophagocyticlymphohistiocytosisacaseseriesandreviewoftheliterature
AT robertfulmer ehrlichiosisassociatedhemophagocyticlymphohistiocytosisacaseseriesandreviewoftheliterature
AT meganhamner ehrlichiosisassociatedhemophagocyticlymphohistiocytosisacaseseriesandreviewoftheliterature
AT wissamelatrouni ehrlichiosisassociatedhemophagocyticlymphohistiocytosisacaseseriesandreviewoftheliterature